pharma

M&A activity has begun in the New Year, with the pharma sector leading from the front. Earlier this week, the Wall Street Journal reported Celgene Corporation (NASDAQ: CELG) is pursuing Juno Therapeutics Inc (NASDAQ: JUNO). The report triggered a massive 52-percent upward move in shares of...

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced an offering of 21 million shares of its common stock at $2.58 per share in November, and at least one Wall Street analyst said another dilutive offering is imminent. The Analyst Oppenheimer's Derek Archila downgraded Synergy...

If an 8-percent quarterly dividend increase is any indication, Eli Lilly and Co (NYSE: LLY) is confident of its growth potential. Its optimism echoes with one Wall Street analyst.  The Rating Argus analyst David Toung upgraded Eli Lilly from Hold to Buy with a $115 price target. The Thesis...

The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited incremental reaction, with the direction and magnitude of the moves dependent on the market...

Pharmaceutical companies breathed a sigh of relief when Donald Trump prevailed on Election Day. His opponent, Hillary Clinton, had made prescription drug pricing a centerpiece of her campaign. However, according to Bernstein analyst Tim Anderson, pharma stocks may not be off the hook when Trump...

Abstracts for the ASCO 2016 meeting were released on Wednesday evening. With the event only a couple of weeks away, JPMorgan analyst Chris Schott took a look at what investors can expect from the ASCO presentations of four big-name pharma companies. For Eli Lilly and Co (NYSE: LLY), ASCO will be...

Earlier this year pharmaceutical firms began to worry about the upcoming 2016 elections after Presidential hopeful Hillary Clinton announced plans to regulate drug pricing further to ensure that healthcare costs don't skyrocket. While that proposal was well received by consumers, drug...

Eli Lilly and Co (NYSE: LLY) shares are plunging nearly 8.0 percent in early trading on Monday after the company announced that it is discontinuing development of cardiovascular disease treatment drug evacetrapib because of disappointing efficacy. Here’s a look at what shareholders can...

It seems as if mergers and acquisitions in the healthcare sector has become commonplace, with a lot of biotech companies being main targets. Not a week goes by without multiple discussions about the battle between Valeant Pharmaceuticals (NYSE: VRX) and Allergan(NYSE: AGN). Last week brought...

In this momentum-driven market, sector or company-specific news can have a significant impact on the price of individual issues. Wall Street analysts weighing in on the issue may also add to the momentum already in place. An example is Achillion Pharmaceuticals (NASDAQ: ACHN), where all of...

With January effect not producing the most promising results for the overall market, one sector that did was the pharma sector. So far this year, this sector has produced eight of the top ten percentage gainers. The sector, primarily known for producing big winners and big losers, has...